Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically.

Slides:

Advertisements

Similar presentations

Modification of ASC1 by UFM1 Is Crucial for ERα Transactivation and Breast Cancer Development Hee Min Yoo, Sung Hwan Kang, Jae Yeon Kim, Joo Eun Lee, Min.

Advertisements

Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors Ji-Man Kang, Yae-Jean Kim,

CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.

Circ Cardiovasc Interv

Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL.

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation Sung-Doo.

Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.

Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.

Unrelated Donor Bone Marrow Transplants for Severe Aplastic Anemia with Conditioning Using Total Body Irradiation and Cyclophosphamide Sung-Yong Kim,

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia Sung-Eun Lee, Ji Yoon Lee, A-Reum Han, Hee-Sun.

Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease Meerim Park, Soo.

Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.

Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.

Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome

CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.

Sabina Kersting, Leo F. Verdonck

Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors Ji-Man Kang, Yae-Jean Kim,

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Sung-Soo Park, Young-Woo.

Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute.

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.

Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation Seong-Gil.

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Diagnostic and Prognostic Value of Mitochondrial DNA Minisatellites after Stem Cell Transplantation Eun Jeong Won, Hye Ran Kim, Hwan Young Kim, Hoon.

Polymorphisms in Genes That Regulate Cyclosporine Metabolism Affect Cyclosporine Blood Levels and Clinical Outcomes in Patients Who Receive Allogeneic.

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

What is quality in a transplant program?

Favorable Outcome in Patients with Acute Myelogenous Leukemia with the Nucleophosmin Gene Mutation Autografted after Conditioning with High-Dose Continuous.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives Minakshi Raj, Sung Won Choi,

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Clinical Lymphoma, Myeloma and Leukemia

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Mammen Chandy Biology of Blood and Marrow Transplantation

Successful Engraftment with Fludarabine, Cyclophosphamide, and Thymoglobulin Conditioning Regimen in Unrelated Transplantation for Severe Aplastic Anemia:

Treatment versus Transplant for Challenging Hematologic Disorders

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Mary Eapen Biology of Blood and Marrow Transplantation

Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory.

Graft-versus-Tumor Effect According to Type of Graft-versus-Host Disease Defined by National Institutes of Health Consensus Criteria and Associated Outcomes

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically Normal Acute Myelogenous Leukemia Jae-Ho Yoon, Hee-Je Kim, Seung-Hwan Shin, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Ji-Hyang Lim Biology of Blood and Marrow Transplantation Volume 19, Issue 6, Pages 958-966 (June 2013) DOI: 10.1016/j.bbmt.2013.03.013 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Higher WT1 expression ≥ 1.0 at diagnosis showed inferior OS and DFS (n = 104, 52 versus 52). (B) Higher WT1 expression ≥0.15 (higher than upper 25% level) at postinduction chemotherapy showed inferior OS and DFS (n = 104, 52 versus 52). (C) Higher WT1 expression ≥.05 (higher than upper 25% level) at pre-HSCT showed inferior OS and DFS after HSCT (n = 68, 17 versus 51). Biology of Blood and Marrow Transplantation 2013 19, 958-966DOI: (10.1016/j.bbmt.2013.03.013) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) WT1 DR more than 1-log at postinduction chemotherapy showed superior OS and DFS (n = 104, 64 versus 40). (B) WT1 DR more than 1-log at pre-HSCT also showed superior OS and DFS after HSCT (n = 68, 46 versus 22). Biology of Blood and Marrow Transplantation 2013 19, 958-966DOI: (10.1016/j.bbmt.2013.03.013) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Subgroup analyses associated with relations between diagnostic WT1 expression and WT1 DR at pre-HSCT. Four subgroups: Subroup1 (n = 20), diagnostic WT1 < 1.0 and WT1 DR ≥ 1-log; Subgroup 2 (n = 18), diagnostic WT1 < 1.0 and WT1 DR < 1-log; Subgroup 3 (n = 26), diagnostic WT1 ≥ 1.0 and WT1 DR ≥ 1-log; Subgroup 4 (n = 4), diagnostic WT1 ≥ 1.0 and WT1 DR < 1-log. Subgroup 1 showed the most favorable outcomes. Subgroup 3 showed more favorable survival curves than Subgroup 2. Biology of Blood and Marrow Transplantation 2013 19, 958-966DOI: (10.1016/j.bbmt.2013.03.013) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 WT1 expression analysis in the NPM1-wild-type/FLT3-ITD–negative CN-AML. (A) Higher WT1 expression at diagnosis showed inferior OS and DFS. (B) Higher WT1 expression at postinduction chemotherapy also showed inferior OS and DFS. (C) WT1 DR more than 1-log also showed superior OS and DFS after HSCT in the NPM1-wild-type/FLT3-ITD–negative CN-AML subgroup. Biology of Blood and Marrow Transplantation 2013 19, 958-966DOI: (10.1016/j.bbmt.2013.03.013) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions